Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SPARC's board, at its May 19, 2025 meeting, approved audited standalone and consolidated results for Q4 and FY25. Standalone revenue from operations fell to ₹71.77 crore (FY24: ₹75.55 crore), with a net loss of ₹345.22 crore versus ₹388.11 crore in FY24. Other equity is deeply negative at ₹(253.07) crore standalone and ₹(249.40) crore consolidated, and the company relies on a support letter from its promoter group to maintain going concern status. The board approved a proposal to raise up to ₹1,800 crore through securities in one or more tranches, subject to shareholder approval via a special resolution at the upcoming AGM. It also appointed Ms. Rekha Warriar and Mr. Venkateswarlu Jasti as additional Non-Executive Independent Directors for 5-year terms starting May 19, 2025, and re-appointed Mr. Anilkumar Raghavan as CEO for a further 5 years effective May 25, 2026. KJB & Co. LLP was appointed as Secretarial Auditor for 5 years from FY 2025-26.
Persistent losses and eroded equity highlight the need for fresh capital, and the ₹1,800 crore fund-raise plan could lead to dilution for existing shareholders depending on the instrument and pricing. Continuity at the CEO level and addition of two independent directors lend governance stability, but investors should watch for further details on the fundraising route and the nature of promoter support.